232 related articles for article (PubMed ID: 8126059)
1. Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384.
Nishino Y; Schneider MR; Michna H
J Cancer Res Clin Oncol; 1994; 120(5):298-302. PubMed ID: 8126059
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.
Li S; Lévesque C; Geng CS; Yan X; Labrie F
Breast Cancer Res Treat; 1995 May; 34(2):147-59. PubMed ID: 7647332
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of the antitumor effect of tamoxifen by combination with the antiprogestin onapristone.
Nishino T; Ishibashi K; Hirtreiter C; Nishino Y
J Steroid Biochem Mol Biol; 2009 Sep; 116(3-5):187-90. PubMed ID: 19500671
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of the novel anti-estrogen EM-800 and medroxyprogesterone acetate on estrone-stimulated growth of dimethylbenz[a]anthracene-induced mammary carcinoma in rats.
Luo S; Stojanovic M; Labrie C; Labrie F
Int J Cancer; 1997 Nov; 73(4):580-6. PubMed ID: 9389575
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.
Kawamura I; Mizota T; Kondo N; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1991 Oct; 57(2):215-24. PubMed ID: 1812300
[TBL] [Abstract][Full Text] [Related]
6. Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Kelly PA; Asselin J; Caron MG; Labrie F; Raynaud JP
J Natl Cancer Inst; 1977 Mar; 58(3):623-8. PubMed ID: 402479
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies.
Michna H; Schneider MR; Nishino Y; el Etreby MF
Breast Cancer Res Treat; 1989 Dec; 14(3):275-88. PubMed ID: 2514814
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the rat.
Schneider MR; Michna H; Nishino Y; el Etreby MF
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):691-701. PubMed ID: 2497018
[TBL] [Abstract][Full Text] [Related]
9. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG
Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibitory activity of a new antiestrogen, RU 16 117, on the development and growth of DMBA-induced rat mammary adenocarcinoma.
Labrie F; Kelly PA; Asselin J; Raynaud JP
Recent Results Cancer Res; 1976; (57):109-20. PubMed ID: 827798
[TBL] [Abstract][Full Text] [Related]
11. Anti-implantation activity of antiestrogens and mifepristone.
Dao B; Vanage G; Marshall A; Bardin CW; Koide SS
Contraception; 1996 Oct; 54(4):253-8. PubMed ID: 8922879
[TBL] [Abstract][Full Text] [Related]
12. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
13. Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia.
Sibonga JD; Dobnig H; Harden RM; Turner RT
Endocrinology; 1998 Sep; 139(9):3736-42. PubMed ID: 9724025
[TBL] [Abstract][Full Text] [Related]
14. Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(A)anthracene-induced mammary carcinoma in the rat.
Luo S; Sourla A; Labrie C; Bélanger A; Labrie F
Endocrinology; 1997 Oct; 138(10):4435-44. PubMed ID: 9322961
[TBL] [Abstract][Full Text] [Related]
15. Progesterone receptor involvement in independent tumor growth in MPA-induced murine mammary adenocarcinomas.
Montecchia MF; Lamb C; Molinolo AA; Luthy IA; Pazos P; Charreau E; Vanzulli S; Lanari C
J Steroid Biochem Mol Biol; 1999 Jan; 68(1-2):11-21. PubMed ID: 10215033
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats.
Zaccheo T; Giudici D; Di Salle E
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):677-80. PubMed ID: 8476783
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the estradiol-mediated endometrial gland formation by the antigestagen onapristone in rabbits: relationship to uterine estrogen receptors.
Chwalisz K; Hegele-Hartung C; Fritzemeier KH; Beier HM; Elger W
Endocrinology; 1991 Jul; 129(1):312-22. PubMed ID: 2055191
[TBL] [Abstract][Full Text] [Related]
18. Direct actions of estradiol on the anterior pituitary gland are required for hypothalamus-dependent lactotrope proliferation and secretory surges of luteinizing hormone but not of prolactin in female rats.
Yin P; Kawashima K; Arita J
Neuroendocrinology; 2002 Jun; 75(6):392-401. PubMed ID: 12065892
[TBL] [Abstract][Full Text] [Related]
19. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.
Lykkesfeldt AE; Larsen SS; Briand P
Int J Cancer; 1995 May; 61(4):529-34. PubMed ID: 7759159
[TBL] [Abstract][Full Text] [Related]
20. 3,3'4,4'-Tetrachlorobiphenyl exhibits antiestrogenic and antitumorigenic activity in the rodent uterus and mammary cells and in human breast cancer cells.
Ramamoorthy K; Gupta MS; Sun G; McDougal A; Safe SH
Carcinogenesis; 1999 Jan; 20(1):115-23. PubMed ID: 9934858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
